Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study on the Use of Racotumomab Anti-idiotype Antibody in Patients With Pediatric Malignancies That Express N-glycolylated Gangliosides and Are Resistant to Conventional Treatment.

NCT01598454 is registered in ClinicalTrials.gov with Laboratorio Elea Phoenix S.A. as lead sponsor.

NCT NCT01598454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01598454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study on the Use of Racotumomab Anti-idiotype Antibody in Patients With Pediatric Malignancies That Express N-glycolylated Gangliosides and Are Resistant to Conventional Treatment.
Lead sponsor
Laboratorio Elea Phoenix S.A.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2011
Completion date
June 30, 2015
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing's sarcoma, glioma, neuroblastoma, retinoblastoma, wilm's tumor